Investors & Media

Corporate Profile

Neumentum is dedicated to becoming a leading non-opioid analgesic and neurology specialty pharmaceutical company. More than 100 million Americans suffer from chronic or acute pain, while another 100 million suffer from various neurological disorders, including migraines, low back pain and neck pain.1 Pain medications are often used to help treat these conditions.

Many patients experiencing moderate to severe pain receive prescription opioids, though treatment with opioids comes with inherent risks. Neumentum’s analgesic product candidates have the potential to provide the benefits of safe and effective pain management without the limitations and risks for abuse and misuse that come with opioids.

Neumentum is led by a world-class executive team of biotech and pharmaceutical industry leaders who have extensive pain and neurology experience, from drug development through commercialization. Neumentum has global rights to five novel non-opioid pain products, the most advanced of which are two phase 3-ready injectable products under development for acute postsurgical pain.

Neumentum Announces Dosing of Patients in Phase I Study Evaluating Its Lead Product Candidate, NTM-001, a Non-Opioid in Development for the Management of Moderately Severe Acute Pain

Neumentum, a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced it completed dosing the first cohort of patients in its phase I study of NTM-001 (pre-mixed bag ketorolac for continuous infusion).

Neumentum Announces Dosing of Patients in Phase I Study

Neumentum Announces Dosing of Patients in Phase I Study Evaluating Its Lead Product Candidate, NTM-001, a Non-Opioid in Development for the Management of Moderately Severe Acute...